SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (7324)1/23/2004 12:02:38 PM
From: rkrw  Read Replies (1) of 10280
 
True on arformoterol. Forgot about that one. Hopefully its as easy as it would seem.

For years I didn't understand why they putted around in so many different areas rather than narrow down with pulmonary as a primary focus. Xopenex, MDI and rr-formoterol could create a real franchise opportunity. Maybe it will come in the next few years. You've posted some great pulmonary combo ideas in the past that sepr would be smart to pay attention to. Pulmonary should be a lot less risky r&d than neuro as well. Can't recall the exact idea, arformoterol plus steroid?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News